StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)

Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –

Exelixis ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Exelixis's ebitda for the twelve months ending Oct 2, 2026 was $1.03B, up 24.3% year over year. For fiscal 2025 it was $901.25M, up 42.3% from the year before. The highest annual figure on record is $901.25M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Jan 2, 2026$901.25M+42.3%
FY2024Jan 3, 2025$633.42M+222.2%
FY2023Dec 29, 2023$196.60M-11.6%
FY2022Dec 30, 2022$222.36M-26.0%
FY2021Dec 31, 2021$300.30M+151.9%
FY2020Jan 1, 2021$119.20M-68.5%
FY2019Jan 3, 2020$377.82M-14.9%
FY2018Dec 28, 2018$443.77M+165.6%
FY2017Dec 29, 2017$167.10M–
FY2016Dec 31, 2016-$27.12M–
FY2015Dec 31, 2015-$120.02M–
FY2014Dec 31, 2014-$222.07M–
FY2013Dec 31, 2013-$197.59M–
FY2012Dec 31, 2012-$116.92M-221.3%
FY2011Dec 31, 2011$96.36M–
FY2010Dec 31, 2010-$80.85M–
FY2009Dec 31, 2009-$109.31M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$275.36M+12.9%
Q2 FY2026Jul 3, 2026$255.40M+15.6%
Q1 FY2026Apr 3, 2026$258.29M+33.0%
Q4 FY2025Jan 2, 2026$242.16M+41.7%
Q3 FY2025Oct 3, 2025$243.96M+70.0%
Q2 FY2025Jul 4, 2025$220.92M-22.0%
Q1 FY2025Apr 4, 2025$194.20M+441.9%
Q4 FY2024Jan 3, 2025$170.85M+93.5%
Q3 FY2024Sep 27, 2024$143.53M–
Q2 FY2024Jun 28, 2024$283.20M+237.6%
Q1 FY2024Mar 29, 2024$35.84M+0.4%
Q4 FY2023Dec 29, 2023$88.31M–
Q3 FY2023Sep 29, 2023-$11.29M-112.8%
Q2 FY2023Jun 30, 2023$83.89M-5.2%
Q1 FY2023Mar 31, 2023$35.69M-59.3%
Q4 FY2022Dec 30, 2022-$42.13M-135.5%
Q3 FY2022Sep 30, 2022$88.28M+56.4%
Q2 FY2022Jul 1, 2022$88.48M-30.2%
Q1 FY2022Apr 1, 2022$87.73M–
Q4 FY2021Dec 31, 2021$118.58M+344.0%
Q3 FY2021Oct 1, 2021$56.43M–
Q2 FY2021Jul 2, 2021$126.68M+63.0%
Q1 FY2021Apr 2, 2021-$1.38M-102.5%
Q4 FY2020Jan 1, 2021$26.71M-66.4%
Q3 FY2020Oct 2, 2020-$40.23M-134.2%
Q2 FY2020Jul 3, 2020$77.74M-17.3%
Q1 FY2020Apr 3, 2020$54.98M-36.5%
Q4 FY2019Jan 3, 2020$79.58M-30.0%
Q3 FY2019Sep 27, 2019$117.70M-7.2%
Q2 FY2019Jun 28, 2019$94.03M+8.6%
Q1 FY2019Mar 29, 2019$86.52M-25.8%
Q4 FY2018Dec 28, 2018$113.64M+200.8%
Q3 FY2018Sep 28, 2018$126.88M+55.8%
Q2 FY2018Jun 29, 2018$86.58M+216.0%
Q1 FY2018Mar 30, 2018$116.68M+470.1%
Q4 FY2017Dec 29, 2017$37.78M-3.5%
Q3 FY2017Sep 30, 2017$81.46M–
Q2 FY2017Jun 30, 2017$27.40M–
Q1 FY2017Mar 31, 2017$20.47M–
Q4 FY2016Dec 31, 2016$39.13M–

More Exelixis figures

See a number that looks wrong?